The drug regulator stated the corporate made claims for the drug product for which it had not obtained approval from the Central Licensing Authority, thereby violating provisions below the New Medication and Medical Trial Guidelines, 2019.
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
DCGI suspends ENTOD’s PresVu eye drops licence after misleading marketing claims, company to challenge order in court
Top Story News
Stay updated with the latest breaking news, trending stories, and in-depth analysis from around the world. Follow Top Story News for real-time updates on politics, business, entertainment, and more. Your trusted source for unbiased news and insightful coverage.
Related Posts
Add A Comment